Literature DB >> 17035404

Evaluation of the 4q32-34 locus in European familial pancreatic cancer.

Julie Earl1, Li Yan, Louis J Vitone, Janet Risk, Steve J Kemp, Chris McFaul, John P Neoptolemos, William Greenhalf, Ralf Kress, Mercedes Sina-Frey, Stephan A Hahn, Harald Rieder, Detlef K Bartsch.   

Abstract

BACKGROUND: Familial pancreatic cancer (FPC) describes a group of families where the inheritance of pancreatic cancer is consistent with an autosomal-dominant mode of inheritance. The 4q32-34 region has been previously identified as a potential locus for FPC in a large American family.
METHODS: The region was allelotyped in 231 individuals from 77 European families using nine microsatellite markers, and haplotyping was possible in 191 individuals from 41 families. Families were selected based on at least two affected first-degree relatives with no other cancer syndromes.
RESULTS: Linkage to most of the locus was excluded based on LOD scores less than -2.0. Eight families were excluded from linkage to 4q32-34 based on haplotypes not segregating with the disease compared with a predicted six to seven families. Two groups of families were identified, which seem to share common alleles within the minimal disease-associated region of 4q32-34, one group with an apparently earlier age of cancer death than the other pancreatic cancer families. Four genes were identified with potential tumor suppressor roles within the locus in regions that could not be excluded based on the LOD score. These were HMGB2, PPID, MORF4, and SPOCK3. DNA sequence analysis of exons of these genes in affected individuals and in pancreatic cancer cell lines did not reveal any mutations.
CONCLUSION: This locus is unlikely to harbor a FPC gene in the majority of our European families.

Entities:  

Mesh:

Year:  2006        PMID: 17035404     DOI: 10.1158/1055-9965.EPI-06-0376

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  23 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

Review 2.  Review of screening for pancreatic cancer in high risk individuals.

Authors:  Alina Stoita; Ian D Penman; David B Williams
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 3.  Hereditary pancreatic cancer.

Authors:  Shilpa Grover; Sapna Syngal
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

Review 4.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

5.  The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma.

Authors:  Toru Takeda; Hiroto Izumi; Shohei Kitada; Hidetaka Uramoto; Takashi Tasaki; Li Zhi; Xin Guo; Yuichiro Kawatsu; Tomoko Kimura; Seichi Horie; Atsunori Nabeshima; Hirotsugu Noguchi; Ke-Yong Wang; Yasuyuki Sasaguri; Kimitoshi Kohno; Sohsuke Yamada
Journal:  Tumour Biol       Date:  2014-07-26

6.  German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.

Authors:  Ralph Schneider; Emily P Slater; Mercede Sina; Nils Habbe; Volker Fendrich; Elvira Matthäi; Peter Langer; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

Review 7.  Update on familial pancreatic cancer.

Authors:  Ralph H Hruban; Marcia I Canto; Michael Goggins; Richard Schulick; Alison P Klein
Journal:  Adv Surg       Date:  2010

Review 8.  Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.

Authors:  Shiro Urayama
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 9.  Pancreatic cancer screening.

Authors:  Eun Ji Shin; Marcia Irene Canto
Journal:  Gastroenterol Clin North Am       Date:  2012-01-05       Impact factor: 3.806

Review 10.  Innovations in proteomic profiling of cancers: alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology.

Authors:  Gilbert S Omenn; Rajasree Menon; Yang Zhang
Journal:  J Proteomics       Date:  2013-04-17       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.